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Abstract
Background: Ertapenem is a once-daily broad spectrum carbapenem that is increasingly used to treat
polymicrobial osteomyelitis due to diabetic foot and traumatic wound infections. However, limited data exists on
ertapenem use for osteomyelitis. This study aimed to characterize outcomes and adverse effects with empiric use
of ertapenem for osteomyelitis.
Findings: A total of 112 patients presenting to Duke, Durham Regional or Durham VA Medical Centers with a
suspected diagnosis of osteomyelitis and ertapenem use from 11/2001 to 8/2009 were screened, and 12 subjects
met inclusion criteria for the study. Mean age was 60 ± 16 years, 68% were female, 75% were Caucasian, and the
most common comorbidities included diabetes (58%), peripheral vascular disease (42%), and history of tobacco use
(75%). Over half of the patients presented to a primary care clinic or emergency room greater than six months
after the onset of clinical symptoms. Bone culture was obtained for diagnostic guidance in only two cases; and
surgical intervention was pursued in three cases. Patients received a mean duration of 34.6 ± 7.8 days of therapy,
and in three cases, subsequent suppressive oral antibiotics were given. Six (50%) patients met criteria for clinical
success, defined as resolution of clinical signs and symptoms of infection such that discontinuation of antibiotics
was deemed appropriate at end of ertapenem therapy, without recurrence at one year follow-up. No adverse drug
effects were noted.
Conclusions: In this case series of mostly community-acquired, lower extremity osteomyelitis, bone biopsy was
infrequent, and an average six-week course of empiric ertapenem was well-tolerated with curative rates of 50% at
one year.
Introduction
Osteomyelitis is a common, costly clinical problem [1].
Challenges to osteomyelitis treatment include difficulty
identifying the offending pathogen and the requirement
for a long course of intravenous therapy. Osteomyelitis
due to diabetic foot and traumatic wound infections are
often polymicrobial and require broad-spectrum antibio-
tics to cover gram-positive, gram-negative, and anaerobic
microorganisms. While oral therapy is generally not first-
line for serious infections, regimens including beta lac-
tams, quinolones, cephalosporins, and nitroimidazoles
have been employed in certain populations [2,3]. Current
intravenous options for polymicrobial osteomyelitis ther-
apy include piperacillin/tazobactam, ampicillin/sulbactam,
and imipenem. While these intravenous antimicrobials
provide excellent broad-spectrum coverage, they require
multiple daily doses, which can be inconvenient, particu-
larly in the outpatient setting.
Ertapenem is a broad-spectrum carbapenem with a long
half-life permitting once-daily dosing. This antibiotic has
activity against most invasive bacterial pathogens except
for methicillin-resistant Staphylococcus aureus (MRSA),
enterococci, Pseudomonas aeruginosa,a n dAcinetobacter
baumannii. Since ertapenem does not inhibit metabolism
of cytochrome P450, it has few drug interactions, and has
a side effect profile similar to piperacillin/tazobactam [4].
Given the wide tissue distribution, ease of administration
and limited potential for drug interactions, ertapenem may
be a good option for treating polymicrobial osteomyelitis.
However, there are no randomized control trials and only
a few observational studies [5,6] evaluating the use of erta-
penem for osteomyelitis. Ertapenem was shown to have
similar clinical response rates to piperacillin/tazobactam in
a double-blind randomized controlled study of diabetic * Correspondence: neela.goswami@duke.edu
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excluded from that trial [7]. This study aimed to retro-
spectively analyze data from patients who received ertape-
nem therapy for osteomyelitis to further characterize
outcomes and adverse effects associated with therapy.
Methods
Patients prescribed ertapenem November 2001 through
August 2009 at Duke University, Durham Regional and
Durham VA Medical Centers were identified through
pharmacy records and cross-matched with patients diag-
nosed with osteomyelitis during the same hospital stay.
Patients 18 years or older with an International Classifi-
cation of Disease code (ICD-9) discharge diagnosis of
osteomyelitis who received at least two weeks of ertape-
nem were included in the study. Included subjects
furthermore had to meet the following clinical criteria for
a diagnosis of osteomyelitis: persistent bone pain,
erythema, tenderness, or exposure through open wound
and one or more of the following: (1) positive culture on
bone biopsy; (2) suggestive radiographic findings on CT
scan, MRI or bone scan; and (3) operative findings sug-
gestive of infection [8]. Patients were excluded if (1)
infection involved prosthetic material in which the mate-
rial was not removed, (2) an allergy to imipenem or erta-
penem was documented, (3) initial infection during
studied hospital stay was documented to involve MRSA,
P. aeruginosa, or enterococci, or (4) vancomycin or
another antibiotic was given for over two weeks concur-
rently with ertapenem.
Demographic and clinical data, drug administration
information, and adverse effects were collected on a stan-
dardized case report form. The patient’s clinical episode of
osteomyelitis was classified as an initial episode or recur-
rence (repeat episode of osteomyelitis at current site).
Contiguous osteomyelitis was defined as bone infection
associated with wound infection, osteomyelitis following
surgery or trauma, or cellulitis at the osteomyelitis site
occurring within two weeks prior to diagnosis; hematogen-
ous was defined as any osteomyelitis without a contiguous
focus of infection [6]. Osteomyelitis was considered acute
if symptoms (bone pain, erythema, tenderness, or expo-
sure through an open wound) were present less than four
weeks prior to presentation to a medical provider; other-
wise the infection was classifed as chronic. The episode of
osteomyelitis was categorized as health-care associated if
the patient had transferred to the study hospital from
another healthcare facility, received long-term hemodialy-
sis, was hospitalized during the previous 30 days, or was
receiving chemotherapy for a malignancy [1]. Outcomes at
end of therapy, six weeks, six months, and one year after
therapy were assessed through chart review. Cure was
defined as resolution of clinical signs and symptoms of
infection such that discontinuation of antibiotics was
deemed appropriate, with no recurrence at one year fol-
low-up, and failure was defined as the persistence or pro-
gression of pain, swelling, erythema, or draining sinus
tracts.
The ethical committees that provided approval for the
study were the Duke (Pro00019532), Durham VA (MIRB
1465), and Durham Regional (Pro00019532) Medical Cen-
ters Institutional Review Boards (IRBs). Given the retro-
spective chart-based nature of the study, the IRBs at all
study sites waived the requirement for informed patient
consent. Each patient was assigned a unique study num-
ber, free of any patient identifiers. Data was collected ret-
rospectively, confidentially, and was stored in a central,
password protected database in a secure location.
Findings
A total of 112 inpatients at Duke, Durham VA, and Dur-
ham Regional Medical Centers were hospitalized with an
ICD-9 discharge diagnosis of osteomyelitis and were
reported to have received ertapenem during their hospita-
lization. Of these patients, 12 were excluded because chart
review did not confirm a primary clinical diagnosis of
osteomyelitis, 12 did not receive at least two weeks of erta-
penem, five had positive microbiology data for MRSA
involving the current site of osteomyelitis, and 71 concur-
rently received a second primary antibiotic for at least two
weeks along with ertapenem.
In the remaining 12 patients with a diagnosis of osteo-
myelitis and ertapenem used as main therapy, mean age
was 60 (± 16) years, the majority (68%) were female, and
75% patients were Caucasian. The most common comor-
bidities included diabetes (58%), peripheral vascular disease
(42%), and history of tobacco use (75%). Most patients pre-
sented to a clinic or emergency room after six months of
symptoms from osteomyelitis (see Table 1). Patients were
hospitalized a median of 15 days (interquartile range [IQR]:
0-50 days) after their first medical contact. For 83%
patients, their osteomyelitis was an initial episode (see
Table 2). Over 90% patients had osteomyelitis from a con-
tiguous source, rather than from hematogenous spread,
and 33% patients reported preceding trauma. Onset of clin-
ical symptoms of osteomyelitis occurred in a community
setting in the majority (92%) of patients, while one patient
acquired infection in a local skilled nursing facility. The
most commonly affected site of infection was the toe (50%);
other affected sites included the calcaneus, malleolus, tibia,
and vertebra. MRI was the primary diagnostic imaging
modality in 80% of cases where imaging was used; two
cases of osteomyelitis were diagnosed on clinical grounds
alone. Bone culture was obtained for diagnostic guidance in
only two (17%) of cases. Organisms obtained from bone or
deep tissue culture included methicillin-susceptible Staphy-
lococcus aureus, mixed organisms, Gemella spp., and Kleb-
siella pneumoniae. Initial surgical intervention was pursued
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performed.
In total, patients received a mean duration of 35 ± 8
days of ertapenem. Subsequent suppressive oral antibiotics
were given in three cases. In one case, a patient with ver-
tebral osteomyelitis had recurrence of back pain and new
Enterococcus gallinarum bacteremia within six months
of intravenous therapy; she then received moxifloxacin
400 mg orally daily; and by one year she was considered
cured and antibiotics were discontinued (see Table 2). In
the second case, a diabetic patient with osteomyelitis of
the proximal phalanges continued to have symptoms at
the end of intravenous therapy and was given cephalexin
1 g orally every 8 hours; clinical success was achieved
before 6 months, and antibiotics were stopped. In the
third case, the patient was a diabetic with osteomyelitis of
the lateral malleolus, and with continued signs of infection
at the end of therapy, she was given ciprofloxacin 500 mg
twice daily and clindamycin 150 mg orally three times
daily for three months; she subsequently remained free of
infection at 6 months and at one year. In the total series,
six (50%) had clinical success at one year after therapy.
There were two cases of recurrence at one year. The first
was a 47 year-old man with a remote tibial fracture com-
plicated by previous MRSA infection treated with vanco-
mycin who subsequently developed new drainage from the
tibia during the study hospitalization and underwent deb-
ridement; cultures grew only Gemella spp., and he then
received ertapenem for 39 days. He was considered a clini-
cal success at end of therapy, six weeks, and six months
afterwards. However, at one year he developed new infec-
tion with tissue cultures growing MRSA.
The second clinical recurrence occurred in a 48 year-
old woman with diabetes and peripheral vascular disease
admitted with contiguous osteomyelitis from an infected
diabetic foot ulcer. She received 20 days of empiric erta-
penem with no surgical intervention or subsequent anti-
biotics. After three weeks of the studied hospitalization,
she developed bacteremia with MRSA and Bacteroides
fragilis attributed to acute osteomyelitis at the same site.
Despite various antibiotic regimens, she had subsequent
recurrent flares over one year later.
Discussion
In this series, we present 12 cases of osteomyelitis treated
with ertapenem as the primary antimicrobial. We note a
success rate of 50% among patients who received an aver-
age of six weeks of ertapenem. This success rate is similar
to outcomes found in other retrospective studies of con-
servatively treated contiguous osteomyelitis [2,9]. In a
case series evaluating use of ertapenem for gram-negative
infections, cure rate was found to be 64%, but only five
patients with osteomyelitis were included in that study
[10].
Three patients in our series went on to receive sup-
pressive oral antibiotics;, all three were ultimately free of
symptoms by one year, suggesting that ertapenem may
require adjunctive therapy for clinical cure in complex
cases. In total, only two patients in the series continued
to have symptoms related to osteomyelitis at one year
after therapy. In both cases, recurrent infections were
attributed to MRSA, an organism known to be resistant
to ertapenem.
While traditional teaching for osteomyelitis is to pur-
s u eb o n eb i o p s ya n dc u l t u r ef o ro p t i m a la n t i b i o t i c
choice and management [11,12], the absence of inter-
vention in this series is striking, with only two patients
undergoing bone biopsy. Other studies have shown this
Table 1 Clinical Course Summary of Osteomyelitis Patients Treated with Ertapenem (N = 12)
Time from Clinical Symptoms to Medical Contact N (%)
Less than 1 Month 3 (25.0)
1-6 Months 2 (16.7)
Greater than 6 Months 7 (58.3)
Median Days from Medical Contact to Hospital Admission 14.5 (IQR: 0-49.5)
Bone Culture Obtained for Diagnosis 2 (16.7)
Initial Surgical Intervention 3 (25.0)
Repeat Surgery Performed 1 (33.3)
Mean Duration of Ertapenem Treatment, Days 34.6 (7.8)
Clinical Cure Achieved
£ 6 (50.0)
Adverse Effects from Ertapenem
¥ 0 (0.0)
Subsequent Suppressive Oral Antibiotics Prescribed 3 (25.0)
Mean Time of Clinical Follow-up after Osteomyelitis Hospitalization, Weeks 115.6 (68.5)
£Clinical cure is defined as resolution of clinical signs and symptoms of infection such that discontinuation of antibiotics was deemed appropriate at end of
ertapenem therapy, and there was no recurrence of symptoms of osteomyelitis at one year.
¥Adverse effects evaluated include: rash, nausea, vomiting, diarrhea, seizure, altered mental status, hepatitis, renal insuffiency, and hematologic abnormalities.
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Page 3 of 6Table 2 Individual Demographics, Diagnosis, Treatment, and Outcomes of Osteomyelitis Patients Treated with Ertapenem
Patient Age
(yrs)
Race Gender Comorbidities
€
Diagnosis
¥ Trauma-
related
DiagnosticMethod Surgical
Intervention
No.
Days
on
Erta
Other Antibiotic Outcome at One Year
£
1 47 White Male None Recurrent chronic
contiguous tibial
osteomyelitis
Yes Bone culture Soft tissue
debridement
39 None F-Infection cleared at
end of therapy, but
recurred by one year
2 56 White Female COPD, DM,
Pancreatic
cancer
Initial chronic
hematogenous
vertebral
osteomyelitis
Yes Deep tissue culture None 39 Suppressive moxifloxacin following
ertapenem
F-Did not clear infection
at end of therapy, but
cleared by one year
3 70 White Male CAD, PVD Initial chronic
contiguous tibial
osteomyelitis
Yes Bone culture Bone
debridement
33 None S-Infection cleared at
end of therapy without
recurrence at one year
4 41 White Female None Initial acute
contiguous toe
osteomyelitis
Yes MRI None 43 Amoxicillin/clavulanate for 20 days preceding
ertapenem
S-Infection cleared at
end of therapy without
recurrence at one year
5 72 White Female PVD, DM, CKD Initial chronic
contiguous toe
osteomyelitis
Not
known
MRI None 41 See footnote
1
Suppressive cephalexin following ertapenem
F- Did not clear
infection at end of
therapy, but cleared by
one year
6 64 Black Female PVD, DM Recurrent chronic
contiguous
malleolar
osteomyelitis
Not
known
MRI None 35 Vancomycin and ampicillin/sulbactam for 6
days preceding ertapenem; suppressive
ciprofloxacinclindamycin following ertapenem
F- Did not clear
infection at end of
therapy, but cleared by
one year
7 79 White Female None Initial chronic
contiguous
calcaneal
ostemyelitis
No Bone scan None 24 None S-Infection cleared at
end of therapy without
recurrence at one year
8 76 White Female Neurologic
disease
Initial acute
contiguous
calcaneal
osteomyelitis
No MRI Amputation 26 Imipenem for 14 days following therapy S-Infection cleared at
end of therapy without
recurrence at one year
9 47 White Female DM Initial chronic
contiguous toe
osteomyelitis
Not
known
MRI None 42 Piperacillin/tazobactam for 9 days prior to
ertapenem
S-Infection cleared at
end of therapy without
recurrence at one year
10 37 White Male DM Initial chronic
contiguous toe
osteomyelitis
No MRI None 31 Ampicillin/sulbactam for 3 days prior to
ertapenem
S-Infection cleared at
end of therapy without
recurrence at one year
11 48 Black Female PVD, DM Initial acute
contiguous toe
osteomyelitis
No Plain film None 20 Vancomycin for 4 days, piperacillin/
tazobactam, 3 days, ceftriaxone for 2 days, all
prior to ertapenem
F-Did not clear infection
at end of therapy, nor
by one year
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6Table 2 Individual Demographics, Diagnosis, Treatment, and Outcomes of Osteomyelitis Patients Treated with Ertapenem (Continued)
12 86 Black Male CAD, PVD, DM Initial chronic
contiguous toe
osteomyelitis
No MRI None 42 Piperacillin/tazobactam for 5 days prior to
ertapenem
F- Did not clear
infection at end of
therapy, but cleared by
one year
€Comorbidities include chronic obstructive pulmonary disease (COPD), coronary artery disease (CAD), peripheral vascular disease (PVD), diabetes mellitus (DM), cancer, chronic kidney disease (CKD), liver disease,
connective tissue disorder, neurologic disease, human immunodeficiency virus (HIV), and hepatitis C virus (HCV).
¥Classification of osteomyelitis included the following definitions: Acute = less than four weeks of symptoms (bone pain, erythema, tenderness, or exposure through open wound) prior to presentation to a medical
provider; chronic = greater than or equal to four weeks of symptoms prior to presentation; initial = first episode of osteomyelitis at current site; recurrent = repeat episode of osteomyelitis at current site; contiguous
= any associated wound infection following surgery or trauma or cellulitis at the site of osteomyelitis occurring within two weeks prior to diagnosis; hematogenous = any osteomyelitis without a contiguous focus of
infection associated with the osteomyelitis site.
£S = success, defined as resolution of clinical signs and symptoms of infection such that discontinuation of antibiotics was deemed appropriate at end of ertapenem therapy, and no recurrence at one year; F =
failure, any case not meeting criteria for success.
1Vancomycin for five days, ciprofloxacin for one day, metronidazole for two days, ceftazadime for four days, and imipenem for two days, all preceding ertapenem, and six days of clindamycin concurrently with
ertapenem.
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6is not uncommon in cases where orthopedists and inter-
ventional radiologists are not engaged in the patient’s
care [13]. Whether improving the use of bone biopsy for
diagnostic purposes would improve patient outcomes is
unclear from our data and warrants further study. Con-
comitant surgical intervention (which occurred in three
patients in our series) has also been shown to improve
patient outcomes in serious diabetic foot infections [14],
and may have changed overall cure rates if performed
more consistently in our patients.
This study is retrospective in nature and has a limited
number of study subjects treated with ertapenem alone.
In addition, our results are subject to selection bias since
patients with less severe cases of osteomyelitis may have
been chosen for monotherapy with ertapenem rather
than combination therapy. Nevertheless, this series
demonstrates efficacy and a favorable safety profile for
ertapenem use in lower extremity osteomyelitis. The
study demonstrates curative rates of 50%, and clinical
resolution of infection approaching over 80% at one year,
specifically when surgical intervention and suppressive
oral antibiotics are concurrently employed and MRSA is
unlikely to be a pathogen.
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